SS
0000-0003-4332-4606 Employment
-
Gennova Biopharmaceuticals CEO
Education
-
Central Drug Research Institute Ph.D.
Projects & Funding
Projects & funding information is unavailable.
Publications (20)
- Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field. Save
- Translational development of a tumor junction opening technology. Save
- Development of a process for large scale production of PfRH5 in E. coli expression system. Save
- Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Save
- Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial. Save
- Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. Save
- Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. Save
- Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Save
- Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Save
- Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model. Save